Armata Pharmaceuticals
ARMP
Armata Pharmaceuticals (ARMP) news
Recent news
Armata Pharmaceuticals receives $3.7 million in additional non-dilutive funding from U.S. Department of War to support advancement of AP-SA02 phase 3 development
AInvest Wire · Sep 23, 2026Armata Pharma gets FDA breakthrough designation for AP-SA02
Armata Pharma has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug AP-SA02 in the treatment of advanced solid tumors with specific genetic mutations [1]. This designation is intended to expedite the development and review of…
AInvest Wire · Sep 14, 2026Armata Pharmaceuticals, - To initiate phase 3 superiority study of AP-SA02 in H2 2026
AInvest Wire · Sep 14, 2026Armata Pharmaceuticals - adult Phase 3 study for AP-SA02 expected to initiate in second half of 2026
AInvest Wire · Jul 13, 2026Armata Pharmaceuticals - FDA defers pediatric studies for AP-SA02 until adult Phase 3 data generated
AInvest Wire · Jul 13, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.